Voyageur Pharmaceuticals Ltd. Stock OTC Markets
Stocks
VYYRF
CA92918C1014
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1125 USD | +17.19% |
|
+17.19% | -13.53% |
| Market Cap | 33.95M 24.36M 21.07M 19.68M 18.05M 2.32B 34.49M 231M 90.61M 1.16B 91.47M 89.47M 3.84B | P/E 2024 |
-5.24x | P/E 2025 | -7.5x |
|---|---|---|---|---|---|
| Enterprise Value | 33.72M 24.19M 20.93M 19.54M 17.93M 2.3B 34.26M 229M 90M 1.15B 90.85M 88.87M 3.82B | EV / Sales 2024 |
-
| EV / Sales 2025 | 2,423,581,172x |
| Free-Float |
93.07% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | +17.19% | ||
| 1 week | +17.19% | ||
| Current month | +17.19% | ||
| 1 month | +12.50% | ||
| 3 months | +50.00% | ||
| 6 months | +2.27% | ||
| Current year | -13.53% |
| 1 week | 0.1 | 0.11 | |
| 1 month | 0.1 | 0.11 | |
| Current year | 0.01 | 0.2 | |
| 1 year | 0 | 0.2 | |
| 3 years | 0 | 0.25 | |
| 5 years | 0 | 0.25 | |
| 10 years | 0 | 0.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
Brent Willis
CEO | Chief Executive Officer | - | 01/07/2019 |
| Director of Finance/CFO | - | 17/08/2022 | |
Iryna Saranchova
CTO | Chief Tech/Sci/R&D Officer | - | 17/09/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Brent Willis
BRD | Director/Board Member | - | 06/12/2017 |
Brad Willis
BRD | Director/Board Member | - | 01/07/2019 |
Eric Pommer
CHM | Chairman | - | 30/04/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +17.19% | +17.19% | - | - | 24.19M | ||
| -0.52% | +3.21% | +85.02% | +161.12% | 1,062B | ||
| +0.88% | +1.13% | +51.13% | +49.76% | 619B | ||
| +0.89% | -1.95% | +23.73% | +63.67% | 431B | ||
| +0.71% | +3.93% | +47.75% | +38.58% | 358B | ||
| +0.64% | -0.63% | +36.39% | +41.44% | 293B | ||
| +0.39% | -6.48% | +7.62% | +9.04% | 247B | ||
| +1.51% | +6.69% | +44.34% | +62.47% | 219B | ||
| +3.92% | -7.80% | +5.39% | -42.52% | 200B | ||
| +1.80% | +2.30% | +20.79% | +65.13% | 162B | ||
| Average | +2.77% | -1.90% | +35.79% | +49.85% | 399.14B | |
| Weighted average by Cap. | +0.66% | -0.83% | +49.00% | +76.10% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | 0.01 0.01 0.01 0.01 0.01 0.8 0.01 0.08 0.03 0.4 0.03 0.03 1.32 |
| Net income | -1.71M -1.22M -1.06M -989K -908K -117M -1.73M -11.61M -4.56M -58.43M -4.6M -4.5M -193M | -3.53M -2.53M -2.19M -2.05M -1.88M -241M -3.59M -24.02M -9.43M -121M -9.52M -9.31M -400M |
| Net Debt | -113K -80.81K -69.9K -65.28K -59.88K -7.69M -114K -766K -301K -3.85M -303K -297K -12.74M | -231K -165K -143K -134K -123K -15.74M -234K -1.57M -615K -7.89M -621K -608K -26.09M |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/08/26 | US$0.1125 | +17.19% | 6,500 |
| 05/08/26 | US$0.0960 | -4.00% | 7,500 |
| 04/08/26 | US$0.1000 | +4.17% | 20,000 |
| 31/07/26 | US$0.0960 | -2.04% | 10,000 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- VM Stock
- VYYRF Stock
Select your edition
All financial news and data tailored to specific country editions
















